We all know at this point that high-sugar diets are not good for us. They increase our risk of developing cardiovascular ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

The following is a summary of "Mediastinal staging lymph node probability map in non-small cell lung cancer,” published in the March 2025 issue of Respiratory Research by Bordas-Martinez et al.

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Lung cancer rates vary by subtype and adenocarcinoma incidence worldwide, likely due to differences in air pollution, smoking, and generational patterns.

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

Squamous cell carcinoma. Most people think of skin cancer when they hear the words ... Some examples of cancers that can be adenocarcinomas include lung, pancreatic, and colorectal types.

Esophageal cancer affects the esophagus lining, causing swallowing difficulty and chest pain. Learn what symptoms to look for ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...